Nk Cell Therapy Aml

Allogeneic hematopoietic stem cell transplantation allo hsct has been recognized as the only curative therapy for patients with acute myeloid leukemia aml.

Nk cell therapy aml.

Young acute myeloid leukemia aml patients treated with haploidentical hematopoietic stem cell hsc transplantation demonstrate prolonged survival and diminished rate of relapse. These patients show significant alloreactivity to the aml by donor derived natural killer nk cells making these cells strong candidates for adoptive therapy. Nk cells as consolidation therapy of acute myeloid leukemia in children adolescents the safety and scientific validity of this study is the responsibility of the study sponsor and investigators. It is unknown whether such approaches targeting aml will spare normal hematopoiesis or would need to be used in combination with hematopoietic stem cell transplantation.

This study investigates an innovative treatment for relapsed or refractory acute myeloid leukemia aml exploiting administration of ex vivo generated allogeneic natural killer nk cells with preceding non myeloablative conditioning chemotherapy with or without subsequent in vivo il 2 cytokine support. Nk cells expressing a car against myeloid antigens may combine the benefits of targeting aml cells with nk cell mediated killing. This is a prospective phase i iia study. Listing a study does not mean it has been evaluated by the u s.